Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
$1.36
-0.5%
$1.21
$0.78
$2.55
$19.56M0.55211,382 shs36,469 shs
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$1.99
$2.24
$1.55
$5.59
$13.98M0.55490,390 shs12,349 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.48
-5.8%
$0.37
$0.80
$1.82
$4.35M2.034,760 shs53,000 shs
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
$0.01
-6.5%
$0.01
$0.00
$0.01
$15.34M-2.5756,706 shs75,549 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-0.55%+0.18%+6.45%-18.90%+43.41%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
0.00%-1.00%-16.03%-9.13%-52.07%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-5.78%+2.23%+4.00%-13.73%+33.47%
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
0.00%+31.82%0.00%-3.33%+22.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.7912 of 5 stars
3.55.00.00.04.11.71.3
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
2.7203 of 5 stars
3.55.00.00.01.11.70.6
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50523.85% Upside
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
3.00
Buy$21.00955.28% Upside
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00
N/AN/AN/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ICOTF, LTUS, CMMB, and EDSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
3/13/2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$1.54 per shareN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.18 per shareN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
-$20KN/A0.00N/AN/AN/AN/AN/A

Latest ICOTF, LTUS, CMMB, and EDSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q2 2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.30-$0.30N/A-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
N/A
4.57
4.57
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
1.09
0.91
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
46.05%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
11.91%
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
22.60%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. stock logo
CMMB
Chemomab Therapeutics
2014.36 million12.65 millionNot Optionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
207.02 million2.60 millionNot Optionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
Lotus Pharmaceuticals, Inc. stock logo
LTUS
Lotus Pharmaceuticals
2302.64 billionN/ANot Optionable

Recent News About These Companies

lotus exchange
Lotus Pharmaceuticals Inc Price / Book
Lotus Resources Plans Equity Raise for Uranium Project
Lotus of Love Cancer Inc
Topic: @lotus
2025 Lotus Emira Gets 400-HP Turbo SE Version

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.36 -0.01 (-0.55%)
Closing price 05/29/2025 03:59 PM Eastern
Extended Trading
$1.37 +0.01 (+0.55%)
As of 05/29/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$1.99 0.00 (0.00%)
Closing price 05/29/2025 03:59 PM Eastern
Extended Trading
$1.98 -0.01 (-0.50%)
As of 05/29/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

iCo Therapeutics stock logo

iCo Therapeutics OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Lotus Pharmaceuticals stock logo

Lotus Pharmaceuticals OTCMKTS:LTUS

$0.0058 0.00 (-6.45%)
As of 05/29/2025 11:54 AM Eastern

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.